Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 80,388 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 80,388 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $67.53, for a total transaction of $5,428,601.64. Following the transaction, the chief executive officer now owns 5,293,005 shares in the company, valued at $357,436,627.65. This represents a 1.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Tempus AI Trading Up 6.1 %

TEM traded up $3.97 during trading on Friday, hitting $68.96. 16,292,734 shares of the company’s stock traded hands, compared to its average volume of 11,766,354. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company’s 50 day simple moving average is $44.36 and its two-hundred day simple moving average is $48.84.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. Vestmark Advisory Solutions Inc. grew its stake in shares of Tempus AI by 148.3% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 122,450 shares of the company’s stock worth $4,134,000 after acquiring an additional 73,132 shares during the period. Raymond James Financial Inc. bought a new position in Tempus AI during the fourth quarter valued at approximately $3,757,000. Victory Capital Management Inc. purchased a new stake in Tempus AI in the fourth quarter worth approximately $216,000. SBI Securities Co. Ltd. purchased a new stake in Tempus AI during the 4th quarter valued at $673,000. Finally, US Bancorp DE bought a new position in shares of Tempus AI during the 4th quarter valued at $80,000. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on TEM. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Loop Capital cut their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.